Shire plc, of Dublin, said the FDA is granting priority review of its supplemental new drug application for Vyvanse (lisdexamfetamine dimesylate) capsules as a treatment for adults with binge eating disorder. The company expects the agency to decide whether to approve the new indication in February 2015.